Videos
Clinical Conversations by Experts
View all
State-of-the-Art Interdisciplinary Management of Prostate Cancer
- The Use of Radioligand Treatments in Metastatic Castration-Resistant Prostate Cancer - Matthew Abramowitz
- Case-Based Discussion on Navigating the Evolving Landscape of Castrate-Resistant Prostate Cancer Management - Oliver Sartor
- Advances in Staging and Personalized Radiation Therapy for High-Risk Localized Prostate Cancer - Leslie Ballas
- An Overview of Treatment Strategies in Localized Prostate Cancer: From Active Surveillance to Intensive Therapy - Neal Shore
- An Overview of Strategies and Therapeutic Advances in Metastatic Prostate Cancer - Rana McKay
- Advances and Challenges in High-Risk CSPC: A Multidisciplinary Approach to Patient Management - Paul Sieber
- Real-World Evidence Informs Clinical Decision-Making in Metastatic Castration-Resistant Prostate Cancer - Alan Bryce View all State-of-the-Art Interdisciplinary Management of Prostate Cancer videos
Beyond Androgen Blockade - Exploring New Pathways for Treating mCRPC and mHSPC
- 2023 Key Learnings in mCRPC Treatments – Alicia Morgans
- PARP Inhibitors: Targeting DNA Repair Pathways - Neal Shore
- Multidisciplinary Approach in the Treatment of Metastatic Prostate Cancer - Robert Dreicer
- PSMA PET as a Biomarker for Advanced Prostate Cancer - Oliver Sartor
- The Critical Intersection of Androgen Receptor Pathways and Cell Cycle Regulation in Prostate Cancer Therapy - Rana McKay
- Treatment Decision Making in mCRPC: The Urologist and Patient “What the Patient Needs to Know” About His Disease and Treatment Options? - Brenda Martone
- Treatment Decision Making in mHSPC: The Medical Oncologist and Patient “What the Patient Needs to Know” About this Disease and Treatment Options? - Brenda Martone
- Broadening Treatment Horizons with CDK4/6 Inhibitors from Breast to Prostate Cancer - Rana McKay View all Beyond Androgen Blockade - Exploring New Pathways for Treating mCRPC and mHSPC videos
Integrating (177Lu)–PSMA-617: A Practical Approach for Urology Clinics
- Integration of Lutetium-177 and the Value of Shared Decisions with Practice Stakeholders - Jeffrey Zemencik
- Expanding the Nuclear Hot Lab to Accommodate Lutetium-177 - Lyanne Gomez
- Finding the Right Patient for Lutetium-177 PSMA Treatment - Kara Cossis
- Coordinating & Transitioning Patient Care for Patients Who Receive Lutetium-177 - Elizabeth Davis View all Integrating (177Lu)–PSMA-617: A Practical Approach for Urology Clinics videos
Artificial Intelligence in Prostate Cancer 2022
- NCCN 2024 Guidelines Endorse Novel Prostate Test for Precision Risk Stratification - Rashid Sayyid & Zachary Klaassen
- Multimodal AI Informing Treatment Decisions in Advanced Prostate Cancer - Gerhardt Attard
- Personalizing Prostate Cancer Therapy Using AI-based Predictive Biomarkers - Paul Nguyen
- Beyond Genomics: AI Informing Decision Making in Prostate Cancer – Ashley Ross View all Artificial Intelligence in Prostate Cancer 2022 videos
Featured Videos
Access and Utilization of Healthcare by Adults with Spina Bifida - Lindsay Hampson & Alejandro Lopez
Probing the Promising Future of Anti-HER2 Therapies for Micropapillary Bladder Cancer - Jeffrey Ross
Quality of Life and Patient-relevant Endpoints With Darolutamide in the ARASENS Trial - Karim Fizazi
A Urologist's Perspective on PSMA-Radioligand Therapy in the Treatment Setting of mCRPC - Neal Shore
Association of Inherited Mutations in DNA Repair Genes with Localized Prostate Cancer – Kara Maxwell
The Stakeholders in Operationalizing an Integrated PSMA Imaging and Therapies Clinic - Kendra Harris
Patient Selection for ADT Treatment with the Oral GnRH Antagonist in Clinical Practice - Ashley Ross
EAU 2024
Latest Videos
Bladder Cancer Videos
New Research Sheds Light on Alternative Treatments for Node-Positive Bladder Cancer - Martin Swinton
Probing the Promising Future of Anti-HER2 Therapies for Micropapillary Bladder Cancer - Jeffrey Ross
DNA Based Markers in High-risk Non-Muscle Invasive BCG Unresponsive Bladder Cancer - Alexander Wyatt
A Patient Perspective on High-Risk Non-Muscle Invasive BCG Unresponsive Bladder Cancer- Karen Sachse
Recent Conference Coverage
Conference Highlights Written by Physician-Scientist
2024 Advanced Prostate Cancer Consensus Conference (APCCC)
- AUA 2024: Long-term Dementia Risk with Use of Anticholinergic versus Beta-3-Agonist Pharmacotherapy for Overactive Bladder
- AUA 2024: EvoPAR-Prostate01: Phase III, Double-Blind, Placebo-Controlled, 2-Cohort, Randomized Study of Saruparib (AZD5305) in Combination with New Hormonal Agents in Patients with mCSPC +/- HRR Mutations
- AUA 2024: Back to Medical School: Immunology in NMIBC and Neoadjuvant MIBC for the Urologist
SESAUA 2024 Conference Highlights
- SESAUA 2024: State of the Art Lecture: Management of Complications Following RPLND
- SESAUA 2024: Addressing Racial Disparities in Prostate Cancer Prediction Models: External Validation and Comparison of Four Models of Pathological Outcome Prediction before Radical Prostatectomy
- SESAUA 2024: Association of PSA Response and Overall Survival in Patients with mHSPC: Results from the Phase 3 ARASENS Trial
Recent Physician-Scientist Review Articles
State of the Evidence Review Articles
mHSPC
- Novel Targets and Treatment Developments in Metastatic Hormone Sensitive Prostate Cancer
Written by Zachary Klaassen, MD, MSc Associate Professor of Urology Urologic Oncologist Medical College of Georgia, Georgia Cancer Center Augusta, GA and Rashid Sayyid, MD, MSc Urologic Oncology Fellow University of Toronto Toronto, Ontario, Canada
- Prostate Radiotherapy for De Novo, Low Volume Metastatic Hormone Sensitive Prostate Cancer: Is There Benefit?
Written by Rashid Sayyid, MD, MSc and Zachary Klaassen, MD, MSc
PSMA-Targeted Therapy
- Beyond a VISION to Making a SPLASH: Advances in PSMA-Based Theranostics in Prostate Cancer
Written by Zachary Klaassen, MD, MSc, Medical College of Georgia, Augusta, Georgia
Transformative Evidence
Curated by Clinicians: Educational Forum with Videos, Abstracts and Conference Information
ARAMIS Trial
Extended Safety and Tolerability of Darolutamide for Nonmetastatic Castration-Resistant Prostate Cancer and Adverse Event Time Course in ARAMIS.Patients with nonmetastatic castration-resistant prostate cancer (nmCRPC) are usually asymptomatic and seek treatments that improve survival but have a low risk of adverse events. Darolutamide, a structurally distinct androgen receptor inhibitor (ARi), significantly reduced the risk of metastasis and death versus placebo in ARAMIS.
Read MoreADSTILADRIN
Ferring Announces Full Availability of ADSTILADRIN® (nadofaragene firadenovec-vncg) in the U.S.- Patients with high-risk, non-muscle invasive bladder cancer now have greater access to the first and only FDA-approved intravesical gene therapy
- With full supply of ADSTILADRIN ahead of schedule, Ferring ends the temporary ADSTILADRIN Early Experience Program
- Enrollment in ABLE-41 U.S. Real-World Evidence Study is ongoing
Trials in Progress
Curated by Clinicians: Educational Forum with Videos, Abstracts and Conference Information
Masofaniten
ESSA Pharma Presents Updated Phase 1 Masofaniten (EPI-7386) Clinical Data at the 2024 ASCO Genitourinary Cancers Symposium- Combination of masofaniten plus enzalutamide continues to be well tolerated with deep and durable reductions in PSA in patients with mCRPC
- Phase 2 dose expansion currently underway at the RP2CDs of masofaniten 600 mg BID in combination with enzalutamide 160 mg QD
- Across all dosing cohorts, 81% of patients achieved PSA90, 69% of patients achieved PSA90 in less than 90 days, and 63% of patients achieved PSA <0.2ng/mL. While the data are still maturing, median time to PSA progression is currently at 16.6 months.
Pivot-006 Trial
CG Oncology Announces Pricing of Upsized Initial Public Offering
Reno, Nevada (UroToday.com) -- CG Oncology, Inc. (Nasdaq: CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer, announced the pricing of its upsized initial public offering of 20,000,000 shares of its common stock at an initial public offering price of $19.00 per share. All of the shares are being offered by CG Oncology. The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses, are expected to be $380.0 million. CG Oncology’s common stock is expected to begin trading on the Nasdaq Global Select Market on January 25, 2024 under the ticker symbol “CGON.” The offering is expected to close on January 29, 2024, subject to the satisfaction of customary closing conditions. In addition, CG Oncology has granted the underwriters a 30-day option to purchase up to an additional 3,000,000 shares of common stock at the initial public offering price, less underwriting discounts and commissions. Read More